262.40
-1.80 (-0.68%)
| Previous Close | 264.20 |
| Open | 263.00 |
| Volume | 1,084,201 |
| Avg. Volume (3M) | 6,930,791 |
| Market Cap | 5,364,347,904 |
| Price / Earnings (TTM) | 37.49 |
| Price / Earnings (Forward) | 20.62 |
| Price / Sales | 3.25 |
| Price / Book | 4.38 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 |
| TTM Dividend Yield | 0.02% |
| Profit Margin | 8.32% |
| Operating Margin (TTM) | 16.55% |
| Diluted EPS (TTM) | 0.070 |
| Quarterly Revenue Growth (YOY) | 8.20% |
| Quarterly Earnings Growth (YOY) | 50.00% |
| Total Debt/Equity (MRQ) | 71.18% |
| Current Ratio (MRQ) | 1.55 |
| Operating Cash Flow (TTM) | 396.20 M |
| Levered Free Cash Flow (TTM) | 309.75 M |
| Return on Assets (TTM) | 6.06% |
| Return on Equity (TTM) | 11.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (GB) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | CONVATEC GROUP PLC ORD 10P | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.63 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CONVATEC GROUP PLC ORD 10P | 5 B | 0.02% | 37.49 | 4.38 |
| BECTON DICKINSON AND CO BECTON | 47 B | 2.27% | 27.35 | - |
| RESMED INC RESMED ORD SHS | 35 B | 0.80% | 47.35 | - |
| HOLOGIC INC HOLOGIC ORD SHS | 16 B | - | 10.10 | - |
| COOPER COMPANIES INC COOPER ORD | 4 B | - | 4.31 | - |
| TECAN GROUP AG TECAN GROUP ORD | 2 B | 1.87% | 16.55 | - |
|
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 19.75% |
| % Held by Institutions | 64.80% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |